Download - Human iPS cell-Derived Cardiomyocytes ReproCardio2TM as an ... · Human iPS cell-derived cardiomyocytes ReproCardio2TM displays no differences between cell-lots, and exhibits constant

Transcript
Page 1: Human iPS cell-Derived Cardiomyocytes ReproCardio2TM as an ... · Human iPS cell-derived cardiomyocytes ReproCardio2TM displays no differences between cell-lots, and exhibits constant

0

20

40

60

80

100

120

140

160

180

200

prolongation (%)

Bazett (%)

Fredericia (%)

Human iPS cell-Derived Cardiomyocytes ReproCardio2TM as an Analytic Tool for Large-scale Toxicity Screening

Shunsuke Yoshida1, Zachary Yu-Ching Lin1, Joylynn Clark2, Mark Bryant3, Takashi Masai1, Mitsuru Inamura1 1ReproCell, Yokohama, Japan; 2ReproCell, Boston, USA; 3ReproCell, Crewe, UK

Abstract

Materials and Methods

Result

Conclusion & Discussion

The force-frequency relationship in cardiac muscle contraction is different in developmental maturation and pathological states. Hence, cardiac contraction can be utilized for the evaluation of chemical compounds especially when these compounds affect the beating rate. In this study, various chemical stimulations on the contraction of human iPS cell-derived cardiomyocytes ReproCardio2TM were examined with electrophysiological assay as well as calcium-imaging. ReproCardio2TM possess stable BPM and regular QT interval with minimum differences between cell-lots after been thaw from cryopreservation. With the addition of chemical compounds, the extension or reduction of QT-interval can be obtained by both electrophysiological assay and calcium-imaging. Other novel utility of ReproCardio2TM has also been developed. Taken together, ReproCardio2TM is useful for analyzing the effects of chemical compounds on contractile function. Therefore, ReproCardio2TM can be utilized in large-scale screening of large-scale of chemical compounds

ReproCardio2TM KIT (1 full kit for 96 well plate: ReproCELL # RCESD008) 1. 3.3×105 Single cells x 3 cryo-preserved vials 2. Empty Cryo-preserved Cell vial (dummy) 3. Maintenance culture medium (80mL) x 2 4. Coating solution (30mL) x 1 5. Low attachment plate for aggregated cells 6. Attachment plate for Thin-layer / Single cell

Calcium-imaging Assay

FDSS day 0 day 1-3 day 3 day 4-14

Testing compounds

Electrophysiological assay

day 0 day 1-3 day 3 day 4-14

Testing compounds Analyzer

Step 0 1 2 3 4 … 9 … 14 1 Thawing 2 Making loose clump 3 Transfer into MEA assay probe 4 Making Thin layer 5 Drug evaluation 6 Analysis

Step 0 1 2 3 4 … 9 … 14 1 Thawing 2 Making  loose  clump 3 Transfer  into  assay  plate 4 Making  Thin  layer 5 Staining  and  Evaluate  drugs 6 Analysis

Immunocytochemistry

•  Cells ・・・ 10,000 cells / well •  Equipment ・・・ FDSS Hamamatsu •  Ca indicator ・・・ Cal520 (AAT bioquest) •  Assay Medium ・・・ReproCardio assay medium (ReproCELL), Cremophor EL (Sigma)

•  Cells ・・・ 15000 cells / well •  Equipment ・・・ Available (aMED, AXION, MCS) •  Coating ・・・ Fibronectin •  Assay Medium ・・・ ReproCardio assay medium (ReproCELL) or Culture medium (ReproCELL) with FBS •  Option ・・・ 5% CO2 gas/Air

1. Primary antibody: anti-Conexin 43, MYH6/7(Sigma); anti-MLC-2A/2V (Synaptic systems); anti-Troponin (A Bio-Rad company) and anti-Vimentin (Millipore). 2. Secondary antibody: Alexa Fluor 488 (Life Technologies)

Characteristic of ReproCardio2™ MLC2V / DAPI αMHC / DAPI cTnT / DAPI CX43 / DAPI MLC2A / DAPI βMHC / DAPI Vimentin / DAPI

Figure 1. ReproCardio2™ has various cardiac markers like human heart α-MHC and βMHC are the representative cardiac marker during the differentiation from iPS cells and expressed in heart. MLC-2A and MLC-2V are myosin specific marker for the atrium of the mammalian heart and for the ventricle of the mammalian heart, respectively. Cardiac troponin T (cTnT) is a specific marker in human heart and a thin filament protein which takes part in muscle contraction. Cx43 is conniving gap junction found in several organs and cell types, but is most often found in the heart. Those proteins were used as representative cardiac marker. Scale bar : 30 µm.

Electrophysiological Assay utilizing ReproCardio2™

1. MEA ASSAY

Figure 2. Reproducibility of MEA assay: within the lot or between lot To prove there is no drastic difference within the cell lot, thin layers were made from cell clamps from the same vial of ReproCardio2TM. The different clamp-derived thin layers were exposed to various concentration of E4031 from 300 pM to 30 µM. The data obtained from each thin layers were plotted together, and it shows that E4031 has similar prolonging QT interval affect in all thin layer from the same cell lot. To prove cell lots has no drastic difference, we exposed various concentration of E4031 from 300 pM to 30µM to 3 different cell lots. The graphs showed that 3 different cell lots exhibit similar prolonging QT interval that is known for. This demonstrates that ReproCardio2TM has low production bias within lot as well as from lot to lot.

Lot B

Lot A

[ , M ]E4031

0

20

40

60

80

100

120

140

160

180

200

1.E-131.E-12

Prol

onga

tion

(%)

00

20

40

60

80

100

120

140

160

180

200

1.E-10 1.E-09 1.E-08 1.E-07 1.E-06 1.E-05 1.E-04

prolongation (%)

Bazett (%)

Fredericia (%)

Lot B Lot C

E401 concentration (M)

QT

Inte

rval

B

PM

0

20

40

60

80

100

120

140

160

180

200

Na-

K in

terv

al (%

)

0

20

40

60

80

100

120

140

160

180

200

1.E-10 1.E-09 1.E-08 1.E-07 1.E-06 1.E-05 1.E-04

prolongation (%)

Bazett (%)

Fredericia (%)

0

20

40

60

80

100

120

140

160

180

200

Bea

t rat

e (%

)

0

20

40

60

80

100

120

140

160

180

200

1.E-10 1.E-09 1.E-08 1.E-07 1.E-06 1.E-05 1.E-04

Aspirin: Non QT prolongation

0

20

40

60

80

100

120

140

160

180

200

Na-

K in

terv

al (%

)

0

20

40

60

80

100

120

140

160

180

200

prolongation (%)

Bazett (%)

Fredericia (%)

0

50

100

150

200

250

300

0

50

100

150

200

250

300

Bea

t rat

e (%

)

0 0

Verapamil: Ca channel blocker

0

20

40

60

80

100

120

140

160

180

200

0

20

40

60

80

100

120

140

160

180

200

0

20

40

60

80

100

120

140

160

180

200

0

20

40

60

80

100

120

140

160

180

200

prolongation (%)

Bazett (%)

Fredericia (%)

0

Na-

K in

terv

al (%

)

Bea

t rat

e (%

)

β-Adrenergic Agonist : Isoproterenol

0

50

100

150

200

prolongation (%) Bazett (%) Fredericia (%)

0 20 40 60 80

100 120 140 160 180 200

Bea

t rat

e (%

)

0

50

100

150

200

K a

mpl

itude

(%)

K a

mpl

itude

0 20 40 60 80

100 120 140 160 180 200

0

50

100

150

200

0

50

100

150

200

1.E-10 1.E-09 1.E-08 1.E-07 1.E-06 1.E-05 1.E-04

QT

Inte

rval

B

PM

IKr Blocker : E-4031

0

Na-

K in

terv

al (%

)

0 20 40 60 80

100 120 140 160 180 200

Na-

K in

terv

al (%

)

0 20 40 60 80

100 120 140 160 180 200

prolongation (%)

Bazett (%)

Fredericia (%)

0 20 40 60 80

100 120 140 160 180 200

Bea

t rat

e (%

)

0 20 40 60 80

100 120 140 160 180 200

0 20 40 60 80

100 120 140 160 180 200

1.E-13 1.E-12 Na

ampl

itude

(%)

0

50

100

150

200

1.E-10 1.E-09 1.E-08 1.E-07 1.E-06 1.E-05 1.E-04

Na

ampl

itude

QT

Inte

rval

BP

M

Figure 3. The Effects of Various Chemical Compounds on ReproCardio2TM by MEA. To see the affect of different drugs, thin layers were made from cell clamps. The thin layer ReproCardio2TM was exposed to various concentration of drugs from 300 pM to 30 µM. The data was obtained from MCS system, with 2 minutes of drug exposure and 2 minutes of recording.

0 0

Na Blocker : Flecainide Na Blocker : Flecainide

2.Calcium imaging

Contraction Relaxation

Analysis points •  BPM •  AMP (a) •  Positive Slope (b) •  Negative Slope (c) •  PWD (10-90%) (d) etc.

a

b c

d

A.)

Ikr antagonist (E-4031)

Na channel blocker (Flecainide)

0 M (vehicle)

Note. Arrows mean EAD (Arrhythmia)

B.)

BPM AMP

Note. Conc. 0, 30, 100, 300, 3, 30, 100 µM Note. Each dot mean Average ± S.E. (n = 6)

Positive slope ■/Negative slope ● PWD10▲/50●/90■

0 1E-­‐10 1E-­‐09 1E-­‐08 1E-­‐07 1E-­‐06 1E-­‐05 1E-­‐04 1E-­‐03 0 1E-­‐10 1E-­‐09 1E-­‐08 1E-­‐07 1E-­‐06 1E-­‐05 1E-­‐04 1E-­‐03

0 1E-­‐10 1E-­‐09 1E-­‐08 1E-­‐07 1E-­‐06 1E-­‐05 1E-­‐04 1E-­‐03 0 1E-­‐10 1E-­‐09 1E-­‐08 1E-­‐07 1E-­‐06 1E-­‐05 1E-­‐04 1E-­‐03

0  

50  

100  

150  

200  

0  

50  

100  

150  

200  

0  

50  

100  

150  

200  

0  

50  

100  

150  

200  

C.) Aspirin BPM AMP

PWD10▲/50●/90■

0  

50  

100  

150  

200  

0 1E-­‐10 1E-­‐09 1E-­‐08 1E-­‐07 1E-­‐06 1E-­‐05 1E-­‐04 1E-­‐03 0  

50  

100  

150  

200  

0 1E-­‐10 1E-­‐09 1E-­‐08 1E-­‐07 1E-­‐06 1E-­‐05 1E-­‐04 1E-­‐03

0  

50  

100  

150  

200  

0 1E-­‐10 1E-­‐09 1E-­‐08 1E-­‐07 1E-­‐06 1E-­‐05 1E-­‐04 1E-­‐03 0 1E-­‐10 1E-­‐09 1E-­‐08 1E-­‐07 1E-­‐06 1E-­‐05 1E-­‐04 1E-­‐03

0  

50  

100  

150  

200  Positive slope ■/Negative slope ●

Verapamil

BPM AMP

Positive slope ■/Negative slope ● PWD10▲/50●/90■

0 1E-­‐10 1E-­‐09 1E-­‐08 1E-­‐07 1E-­‐06 1E-­‐05 1E-­‐04 1E-­‐03 0 1E-­‐10 1E-­‐09 1E-­‐08 1E-­‐07 1E-­‐06 1E-­‐05 1E-­‐04 1E-­‐03

0 1E-­‐10 1E-­‐09 1E-­‐08 1E-­‐07 1E-­‐06 1E-­‐05 1E-­‐04 1E-­‐03 0 1E-­‐10 1E-­‐09 1E-­‐08 1E-­‐07 1E-­‐06 1E-­‐05 1E-­‐04 1E-­‐03

0  

50  

100  

150  

200  

0  

50  

100  

150  

200  

0  

50  

100  

150  

200  

0  

50  

100  

150  

200  

Isoproterenol BPM AMP

Positive slope ■/Negative slope ● PWD10▲/50●/90■

0 1E-­‐10 1E-­‐09 1E-­‐08 1E-­‐07 1E-­‐06 1E-­‐05 1E-­‐04 1E-­‐03 0 1E-­‐10 zz1E-­‐09 1E-­‐08 1E-­‐07 1E-­‐06 1E-­‐05 1E-­‐04 1E-­‐03

0 1E-­‐10 1E-­‐09 1E-­‐08 1E-­‐07 1E-­‐06 1E-­‐05 1E-­‐04 1E-­‐03 0 1E-­‐10 1E-­‐09 1E-­‐08 1E-­‐07 1E-­‐06 1E-­‐05 1E-­‐04 1E-­‐03

0  

50  

100  

150  

200  

0  

50  

100  

150  

200  

0  

50  

100  

150  

200  

0  

50  

100  

150  

200  

E4031

BPM AMP

Positive slope ■/Negative slope ● PWD10▲/50●/90■ 0 1E-­‐10 1E-­‐09 1E-­‐08 1E-­‐07 1E-­‐06 1E-­‐05 1E-­‐04 1E-­‐03 0 1E-­‐10 1E-­‐09 1E-­‐08 1E-­‐07 1E-­‐06 1E-­‐05 1E-­‐04 1E-­‐03

0 1E-­‐10 1E-­‐09 1E-­‐08 1E-­‐07 1E-­‐06 1E-­‐05 1E-­‐04 1E-­‐03 0 1E-­‐10 1E-­‐09 1E-­‐08 1E-­‐07 1E-­‐06 1E-­‐05 1E-­‐04 1E-­‐03

0  20  40  60  80  100  120  140  160  180  200  

0  20  40  60  80  

100  120  140  160  180  200  

0  20  40  60  80  100  120  140  160  180  200  

0  

50  

100  

150  

200  

250  

300  

350  

400  

Flecainide

Figure 4. The Effects of Various Chemical Compounds on ReproCardio2TM by Calcium-imaging. A) The various parameters can be interpreted from Ca-imaging. B) The change of graph after admitting drugs. ReproCardio2TM was exposed to various concentration of drugs from 300pM-30µM. Ca signal from ReproCardio2TM

can be detected for a hour. The data was obtained from 2 minutes of drug exposure and 2 minutes of recording.

Human iPS cell-derived cardiomyocytes ReproCardio2TM displays no differences between cell-lots, and exhibits constant affects of the drug screening even with different analyzing methods. The utility of ReproCardio2TM is also expandable. This demonstrated that ReproCardio2TM is suitable for the large-scale screening of chemical compounds.

0

E401 concentration (M)

0

20

40

60

80

100

120

140

160

180

200

Prol

onga

tion

(%)

[ , M ]E4031

0

20

40

60

80

100

120

140

160

180

200

1.E-131.E-12

Prol

onga

tion

(%)

00

20

40

60

80

100

120

140

160

180

200

1.E-10 1.E-09 1.E-08 1.E-07 1.E-06 1.E-05 1.E-04

prolongation (%)

Bazett (%)

Fredericia (%)

E401 concentration (M)